Jennifer Kahler

发表

Development of Highly Optimized Antibody–Drug Conjugates against CD33 and CD123 for Acute Myeloid Leukemia

F. Loganzo, C. J. O’Donnell, A. Maderna, 2020, Clinical Cancer Research.

Preclinical Development Preclinical Characterization of OSI-027 , a Potent and Selective Inhibitor of mTORC 1 and mTORC 2 : Distinct from Rapamycin

P. Houghton, P. Gokhale, D. Epstein, 2011 .

Abstract 4487: OSI-027, a potent and selective small molecule mTORC1/mTORC2 kinase inhibitor is mechanistically distinct from rapamycin

P. Gokhale, D. Epstein, A. Crew, 2010 .

Lysosomes and Antibody–Drug Conjugates

P. Sapra, Maureen M. Dougher, M. Sung, 2016 .

OSI-930: a novel selective inhibitor of Kit and kinase insert domain receptor tyrosine kinases with antitumor activity in mouse xenograft models.

G. Wynne, N. Gibson, D. Emerson, 2006, Cancer research.

Temporal quantitation of mutant Kit tyrosine kinase signaling attenuated by a novel thiophene kinase inhibitor OSI-930

Laura A. Sullivan, Siobhan McCormack, F. Petti, 2005, Molecular Cancer Therapeutics.

Preclinical Characterization of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2: Distinct from Rapamycin

P. Houghton, P. Gokhale, D. Epstein, 2011, Molecular Cancer Therapeutics.

Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib.

Stuart Thomson, M. Sliwkowski, M. Romero, 2006, Cancer research.

Imidazo[1,5-a]pyrazines: orally efficacious inhibitors of mTORC1 and mTORC2.

D. Werner, P. Gokhale, N. Gibson, 2011, Bioorganic & medicinal chemistry letters.

in Mouse Xenograft Models Domain Receptor Tyrosine Kinases with Antitumor Activity OSI-930 : A Novel Selective Inhibitor of Kit and Kinase Insert

G. Wynne, N. Gibson, A. Castelhano, 2006 .

Enhanced Antitumor Activity of an Anti-5T4 Antibody–Drug Conjugate in Combination with PI3K/mTOR inhibitors or Taxanes

E. Melamud, E. Rosfjord, P. Sapra, 2015, Clinical Cancer Research.

Discovery of novel insulin-like growth factor-1 receptor inhibitors with unique time-dependent binding kinetics.

P. Gokhale, D. Epstein, E. May, 2013, ACS medicinal chemistry letters.

Novel 6-aminofuro[3,2-c]pyridines as potent, orally efficacious inhibitors of cMET and RON kinases.

M. Albertella, P. Gokhale, D. Epstein, 2013, Bioorganic & medicinal chemistry letters.

Discovery of 7-aminofuro[2,3-c]pyridine inhibitors of TAK1: optimization of kinase selectivity and pharmacokinetics.

M. Albertella, E. May, D. Romashko, 2013, Bioorganic & medicinal chemistry letters.